An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Terminated 92 enrolled Bristol-Myers Squibb

Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether BMS-986258 both monotherapy and in combination with Nivolumab is safe and tolerable in the treatment of advanced malignant tumors.

Timeline

Start: 2018-03-08
Primary completion: 2024-08-29
Completion: 2024-08-29

Outcome

Outcome not reported

Stopped (Business): “Business objectives have changed”

Publications

El Halabi L, Adam J, Gravelle P, Marty V, Danu A, Lazarovici J, Ribrag V, Bosq J, Camara-Clayette V, Laurent C, Ghez D. Expression of the Immune Checkpoint Regulators LAG-3 and TIM-3 in Classical Hodgkin Lymphoma. Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3. doi: 10.1016/j.clml.2020.11.009. Epub 2020 Nov 12.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BMS-986258	Unknown	—	—
Subject	Nivolumab	Monoclonal antibody	—	—
Background	rHuPH20	Protein / enzyme biologic	—	—